Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL
(MedPage Today) -- The non-covalent or reversible Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) demonstrated promising efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 5, 2023 Category: Hematology Source Type: news
No OS Benefit With Ibrutinib in Early-Stage, High-Risk CLL
(MedPage Today) -- Patients with early-stage, high-risk chronic lymphocytic leukemia (CLL) failed to achieve an overall survival (OS) benefit when treated with ibrutinib (Imbruvica) compared with placebo, according to results from the randomized... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 28, 2023 Category: Hematology Source Type: news
CLL: Venetoclax-Obinutuzumab Combo Effective Long Term CLL: Venetoclax-Obinutuzumab Combo Effective Long Term
Patients with chronic lymphocytic leukemia (CLL) experience long-term progression-free survival benefits with 1 year of venetoclax plus obinutuzumab versus a chemotherapy-based regimen.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Fixed-Duration Ibrutinib Plus Venetoclax Beneficial for Leukemia
TUESDAY, June 13, 2023 -- Fixed-duration ibrutinib plus venetoclax is beneficial for patients with chronic lymphocytic leukemia, including those with high risk features, according to a study published online June 7 in Clinical Cancer Research.
John... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 13, 2023 Category: Pharmaceuticals Source Type: news
CAR-T for Chronic Lymphocytic Leukemia Hits Goal of Mid-Stage Trial
(MedPage Today) -- A single infusion of the chimeric antigen receptor (CAR) T-cell product lisocabtagene maraleucel (liso-cel; Breyanzi) was shown to induce complete response or remission in patients with relapsed or refractory chronic lymphocytic... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 12, 2023 Category: Hematology Source Type: news
New CLL Meds: Improved Survival Rates, 1990 –2018 New CLL Meds: Improved Survival Rates, 1990 –2018
Newly published data indicates that widely available medications for chronic lymphocytic leukemia (CLL) have steadily improved overall survival rates over most of the past three decades.MDedge News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 5, 2023 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news
Racial Disparities in CLL: Underrepresentation in Clinical Trials Racial Disparities in CLL: Underrepresentation in Clinical Trials
Joanna Rhodes, MD, MSCE observes differences in the disease biology of chronic lymphocytic leukemia in younger Black patients and emphasizes the need for enrolling non-White patients in clinical trials and ongoing research.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 30, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
A Path to a Career in CLL Clinical Research A Path to a Career in CLL Clinical Research
Joanna Rhodes, MD, MSCE, narrates a change in focus from acute leukemias and bone marrow transplants to the field of chronic lymphocytic leukemia.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 30, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Improving Quality of Life in Patients With CLL: Managing Side Effects From Targeted Therapy Improving Quality of Life in Patients With CLL: Managing Side Effects From Targeted Therapy
Joanna Rhodes, MD, MSCE, reflects on a patient who experienced side effects from targeted agents for chronic lymphocytic leukemia.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 30, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
The Costs of Disparities in the Treatment of Chronic Lymphocytic Leukemia The Costs of Disparities in the Treatment of Chronic Lymphocytic Leukemia
Seema Bhat, MD, reflects on the inequities of access to treatment and deficiencies in research for chronic lymphocytic leukemia.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 30, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Grandad with cancer 'all over his body' cured without chemo after experimental drug trial
Stephen Cossins, 71, was diagnosed with chronic lymphocytic leukaemia - a rare type of cancer that affects the blood and bone marrow - seven years ago. (Source: Daily Express - Health)
Source: Daily Express - Health - May 22, 2023 Category: Consumer Health News Source Type: news
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
CLL: Venetoclax Combos Top First-Line Chemoimmunotherapy CLL: Venetoclax Combos Top First-Line Chemoimmunotherapy
A combination of venetoclax, ibrutinib, and obinutuzumab outperforms first-line chemoimmunotherapy for chronic lymphocytic leukemia in otherwise fit adults with few comorbidities.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
CLL: Black Patients Die Sooner Than White Patients CLL: Black Patients Die Sooner Than White Patients
Although Black patients are much less likely to develop chronic lymphocytic leukemia than are White patients, they are more likely to die sooner from the disease.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 11, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Venetoclax-Obinutuzumab With, Without Ibrutinib Superior in Leukemia
THURSDAY, May 11, 2023 -- For fit patients with chronic lymphocytic leukemia (CLL), venetoclax-obinutuzumab with or without ibrutinib, is superior to chemoimmunotherapy as first-line treatment, according to a study published in the May 11 issue of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 11, 2023 Category: Pharmaceuticals Source Type: news
